

Rajesh K Malik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7018814/publications.pdf>

Version: 2024-02-01

8
papers

219
citations

1684188
5
h-index

1720034
7
g-index

8
all docs

8
docs citations

8
times ranked

322
citing authors

#	ARTICLE	IF	CITATIONS
1	Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	107
2	CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. , 2020, 8, e000847.		45
3	Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials. <i>Cancer Medicine</i> , 2021, 10, 5748-5756.	2.8	26
4	Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer. <i>International Journal of Cancer</i> , 2021, 149, 1463-1472.	5.1	12
5	Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies. <i>Cancer Management and Research</i> , 2021, Volume 13, 6207-6218.	1.9	12
6	Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 689-700.	2.3	9
7	First-in-human Phase 1 safety, PK, and PD study of the CDK4/6 inhibitor G1T28.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2527-2527.	1.6	5
8	Evaluation of targeted bone marrow arrest by G1T28, a CDK4/6 inhibitor in clinical development to reduce chemotherapy-induced myelosuppression.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2529-2529.	1.6	3